
## Michael L Johnson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11669654/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Reportâ€"Part I. Value in Health, 2009, 12, 1044-1052. Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and	0.3	305
2	Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II. Value in Health, 2009, 12,	0.3	246
3	1053-1061 Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Reportâ€"Part III. Value in Health. 2009, 12, 1062-1073.	0.3	234
4	Regression coefficient–based scoring system should be used to assign weights to the risk index. Journal of Clinical Epidemiology, 2016, 79, 22-28.	5.0	141
5	Therapeutic Goal Attainment in Patients With Hypertension and Dyslipidemia. Medical Care, 2006, 44, 39-46.	2.4	90
6	Open Versus Endovascular Abdominal Aortic Aneurysm Repair in VA Hospitals. Journal of the American College of Surgeons, 2006, 202, 577-587.	0.5	89
7	Performance of endovascular aortic aneurysm repair in high-risk patients: Results from the Veterans Affairs National Surgical Quality Improvement Program. Journal of Vascular Surgery, 2007, 45, 227-235.e1.	1.1	88
8	Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. American Journal of Managed Care, 2004, 10, 926-32.	1.1	82
9	International Classification of Diseases, 9th Revision, Clinical Modification Codes in Discharge Abstracts Are Poor Measures of Complication Occurrence in Medical Inpatients. Medical Care, 1997, 35, 589-602.	2.4	73
10	Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimer's and Dementia, 2012, 8, 437-444.	0.8	61
11	Effect of Definition of Mortality on Hospital Profiles. Medical Care, 2002, 40, 7-16.	2.4	55
12	Adapting the Rx-Risk-V for Mortality Prediction in Outpatient Populations. Medical Care, 2006, 44, 793-797.	2.4	53
13	Risk factors for dementia in patients over 65 with diabetes. International Journal of Geriatric Psychiatry, 2011, 26, 749-757.	2.7	49
14	Effect of Chlorhexidine Bathing Every Other Day on Prevention of Hospital-Acquired Infections in the Surgical ICU: A Single-Center, Randomized Controlled Trial*. Critical Care Medicine, 2016, 44, 1822-1832.	0.9	46
15	Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case–Control Study. Journal of the American Geriatrics Society, 2016, 64, 394-400.	2.6	41
16	VHA pharmacy use in veterans with Medicare drug coverage. American Journal of Managed Care, 2009, 15, e1-8.	1.1	37
17	Potentially Inappropriate Anticholinergic Medication Use in Community-Dwelling Older Adults: A National Cross-Sectional Study. Drugs and Aging, 2015, 32, 379-389.	2.7	36
18	Risk of Falls and Fractures in Older Adults Using Atypical Antipsychotic Agents: A Propensity Score–Adjusted, Retrospective Cohort Study. American Journal of Geriatric Pharmacotherapy, 2012, 10, 83-94.	3.0	33

#	Article	IF	CITATIONS
19	Patterns of antihypertensive therapy among patients with diabetes. Journal of General Internal Medicine, 2005, 20, 842-846.	2.6	32
20	Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. American Journal of Geriatric Pharmacotherapy, 2008, 6, 198-204.	3.0	30
21	Risk of Falls and Fractures in Older Adults Using Antipsychotic Agents. Drugs and Aging, 2010, 27, 815-829.	2.7	29
22	Propensity score analysis in observational studies: outcomes after abdominal aortic aneurysm repair. American Journal of Surgery, 2006, 192, 336-343.	1.8	28
23	Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. Journal of the American Geriatrics Society, 2016, 64, 1492-1497.	2.6	28
24	Discharge medication complexity and 30-day heart failure readmissions. Research in Social and Administrative Pharmacy, 2017, 13, 857-863.	3.0	25
25	Comparative Risk of Cerebrovascular Adverse Events in Community-Dwelling Older Adults using Risperidone, Olanzapine and Quetiapine. Drugs and Aging, 2012, 29, 807-817.	2.7	24
26	Potentially inappropriate anticholinergic medication use in older adults with dementia. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 603-612.	1.5	24
27	Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. American Journal of Geriatric Psychiatry, 2016, 24, 485-495.	1.2	24
28	Risk of Cerebrovascular Adverse Events in Older Adults Using Antipsychotic Agents. Journal of Clinical Psychiatry, 2010, 71, 689-698.	2.2	23
29	Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia inÂPatients with Type 2 Diabetes andÂHypertension. Journal of Alzheimer's Disease, 2015, 49, 423-432.	2.6	23
30	Concurrent Use of Stimulants and Second-Generation Antipsychotics Among Children With ADHD Enrolled in Medicaid. Psychiatric Services, 2015, 66, 404-410.	2.0	22
31	Enhancing Statin Adherence Using a Motivational Interviewing Intervention and Past Adherence Trajectories in Patients with Suboptimal Adherence. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1053-1062.	0.9	22
32	In-hospital complications among survivors of admission for congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus. Journal of General Internal Medicine, 1995, 10, 307-314.	2.6	21
33	Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression. Drugs and Aging, 2017, 34, 691-700.	2.7	21
34	The Association of Quality of Care and Occurrence of In-Hospital, Treatment-Related Complications. Medical Care, 1999, 37, 140-148.	2.4	20
35	Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors. Psychiatric Services, 2015, 66, 1333-1340.	2.0	18
36	Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. Research in Social and Administrative Pharmacy, 2020, 16, 329-335.	3.0	16

#	Article	IF	CITATIONS
37	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiology and Drug Safety, 2012, 21, 233-240.	1.9	15
38	Validation of a Model To Predict the Risk of Nephrotoxicity in Patients Receiving Colistin. Antimicrobial Agents and Chemotherapy, 2014, 58, 6946-6948.	3.2	15
39	Does Diabetes Mellitus Alter the Onset and Clinical Course of Vascular Dementia?. Behavioural Neurology, 2010, 23, 145-151.	2.1	13
40	Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. Journal of General Internal Medicine, 2020, 35, 2084-2093.	2.6	13
41	Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. Patient Preference and Adherence, 2020, Volume 14, 2187-2199.	1.8	12
42	Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. Drugs and Aging, 2015, 32, 743-754.	2.7	11
43	<p>Group-Based Trajectory Modeling to Identify Patterns of Adherence and Its Predictors Among Older Adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs)</p> . Patient Preference and Adherence, 2020, Volume 14, 1935-1947.	1.8	11
44	Group-Based Trajectory Models to Identify Sociodemographic and Clinical Predictors of Adherence Patterns to Statin Therapy Among Older Adults. American Health and Drug Benefits, 2019, 12, 202-211.	0.5	11
45	Comparative Performance of Diagnosis-based and Prescription-based Comorbidity Scores to Predict Health-related Quality of Life. Medical Care, 2016, 54, 519-527.	2.4	10
46	A multi-center study of fidaxomicin use for Clostridium difficile infection. SpringerPlus, 2016, 5, 1224.	1.2	10
47	Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 678-686.	1.9	10
48	A quasi-experimental test of an intervention to increase the use of thiazide-based treatment regimens for people with hypertension. Implementation Science, 2007, 2, 5.	6.9	9
49	Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation. Substance Use and Misuse, 2016, 51, 586-597.	1.4	9
50	Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy, 2017, 37, 287-296.	2.6	9
51	Outcomes of "Real-World―Insulin Strategies in the Management of Hospital Hyperglycemia. Journal of the Endocrine Society, 2021, 5, bvab101.	0.2	9
52	The Association of Medicare Drug Coverage with Use of Evidence-Based Medications in the Veterans Health Administration. Annals of Pharmacotherapy, 2009, 43, 1565-1575.	1.9	8
53	Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. Journal of Comparative Effectiveness Research, 2012, 1, 195-206.	1.4	8
54	Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 395-404.	1.9	8

#	Article	IF	CITATIONS
55	Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease. Journal of Psychiatric Research, 2019, 117, 116-121.	3.1	8
56	<p>Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression</p> . Drug, Healthcare and Patient Safety, 2020, Volume 12, 23-30.	2.5	8
57	Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. International Journal of Geriatric Psychiatry, 2021, 36, 684-696.	2.7	8
58	Datapoints: Antipsychotic Utilization and Expenditure Trends Among Elderly Persons. Psychiatric Services, 2007, 58, 1400-1400.	2.0	7
59	Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: A multiple-propensity analysis. Research in Social and Administrative Pharmacy, 2012, 8, 145-156.	3.0	7
60	Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression. Pharmacotherapy, 2016, 36, 38-48.	2.6	7
61	Comparative effectiveness research: guidelines for good practices are just the beginning. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 51-57.	1.4	6
62	Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. Journal of Comparative Effectiveness Research, 2016, 5, 461-473.	1.4	6
63	Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 29-38.	0.9	6
64	Prescribing Patterns of Diuretics in Multiâ€Drug Antihypertensive Regimens. Journal of Clinical Hypertension, 2005, 7, 81-89.	2.0	5
65	Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. International Journal of Infectious Diseases, 2020, 99, 373.	3.3	5
66	Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. American Journal of Geriatric Psychiatry, 2020, 28, 1079-1088.	1.2	5
67	Hepatopancreaticobiliary Values after Thoracoabdominal Aneurysm Repair. Aorta, 2014, 2, 135-142.	0.5	4
68	Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs and Aging, 2022, 39, 453-465.	2.7	4
69	Bedside Barcode Technology: Impact on Medication Administration Tasks in an Intensive Care Unit. Hospital Pharmacy, 2012, 47, 360-366.	1.0	3
70	Prevalence and Factors Associated with Multiple Provider Episodes in Texas: An Epidemiological Analysis of Prescription Drug Monitoring Program Data. Pain Medicine, 2016, 18, pnw250.	1.9	3
71	Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. Annals of Pharmacotherapy, 2016, 50, 96-105.	1.9	3
72	Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Current Medical Research and Opinion, 2021, 37, 1303-1313.	1.9	3

#	Article	IF	CITATIONS
73	Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers. Annals of Gastroenterology, 2022, 35, 182-186.	0.6	3
74	Consumers' intention to use generic-drug discount programmes. Journal of Pharmaceutical Health Services Research, 2012, 3, 205-212.	0.6	2
75	Parents' Expectations to Receive Antibiotic Prescriptions for Children. Journal of Human Behavior in the Social Environment, 2015, 25, 530-551.	1.9	2
76	Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers. Substance Use and Misuse, 2015, 50, 1628-1637.	1.4	2
77	Patient-reported outcomes in light of supportive medications in treatment-naÃ <sup>-</sup> ve lung cancer patients. Supportive Care in Cancer, 2020, 28, 1809-1816.	2.2	2
78	Examination of physicians' adherence to the 2013 ACC/AHA statin/cholesterol guidelines using a framework of awareness to adherence: A cross-sectional study. JRSM Cardiovascular Disease, 2020, 9, 204800402094729.	0.7	2
79	Patient-reported barriers to statin adherence: Excerpts from aÂmotivational interviewing intervention in older adults. Journal of the American Pharmacists Association: JAPhA, 2021, 61, 60-67.e1.	1.5	2
80	Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. Drugs and Aging, 2021, 38, 493-502.	2.7	2
81	Adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments among older patients. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 1351-1358.	1.5	2
82	Concordance Between Electronic Health Record Data and Medicare Part D Claims Data for Oral Anticancer Drug Use. JAMA Network Open, 2020, 3, e203821.	5.9	1
83	Impact of Chlorhexidine Bathing on Antimicrobial Utilization in Surgical Intensive Care Unit. Journal of Surgical Research, 2020, 250, 161-171.	1.6	1
84	Comparative treatment effectiveness of oral fingolimod and conventional injectable diseaseâ€modifying agents in multiple sclerosis. Pharmacotherapy, 2021, 41, 440-450.	2.6	1
85	Potentially inappropriate medication use in elderly breast cancer patients Journal of Clinical Oncology, 2015, 33, 6588-6588.	1.6	1
86	Risk of overactive bladder associated with cholinesterase inhibitors in dementia. Journal of the American Geriatrics Society, 2022, 70, 820-830.	2.6	1
87	Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling. Pharmacotherapy, 2022, 42, 518-528.	2.6	1
88	Chemoprotective effect of metformin against HR+/HER2- breast cancer among women with type-2 diabetes Journal of Clinical Oncology, 2021, 39, 10518-10518.	1.6	0
89	Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Exploratory Research in Clinical and Social Pharmacy, 2021, 2, 100021.	1.0	0
90	The impact of concomitant use of tyrosine kinase inhibitors and proton pump inhibitors on survival in older adults with cancer Journal of Clinical Oncology, 2018, 36, e18732-e18732.	1.6	0